Hirose, Takahisa Toho University
Odawara, Masato Tokyo Medical University
松久, 宗英 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Koshida, Ryusuke Sanofi K.K.
Senda, Masayuki Sanofi K.K.
Tanaka, Yasushi St. Marianna University School of Medicine
Terauchi, Yasuo Yokohama City University
Type 2 diabetes
Chronic kidney disease
Glargine 300 U/mL
Aims: This study investigated the hypoglycemia risk in people with type 2 diabetes (T2D) who initiated or switched to insulin glargine 300 U/mL (Gla-300) by stratifying them by age and renal function.
Methods: We examined data from 4621 people with T2D (1227 insulin-naïve and 3394 insulin-experienced) of the X-STAR study, a prospective, observational, 12-month study conducted from December 2015 to August 2018 in Japan. Participants were stratified by age (<65, 65 to <75, and ≥75 years) and estimated glomerular filtration rate (eGFR) (≥90, 60 to <90, 30 to <60, and <30 mL/min/1.73 m2). Hypoglycemia was defined according to the Ministry of Health, Labour and Welfare manual of Japan.
Results: No apparent increase in the proportion of people who experienced hypoglycemia was found in all subgroups. The proportions were 2.9–3.5% and 2.7–5.2% of insulin-naïve and insulin-experienced people, respectively, for age subgroups, and 2.4–4.7% and 4.6–4.8%, respectively, for eGFR subgroups. The result was similar for HbA1c levels below and at or above 7.0% in all age subgroups.
Conclusions: Our study found no apparent increase in the hypoglycemia risk in people with older age and renal impairment who were administered Gla-300. These results would provide reassuring information on Gla-300 use.
Diabetes Research and Clinical Practice
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
diabres_172_108647.pdf 886 KB